近日，上海微创心脉医疗科技（集团）股份有限公司（以下简称"心脉医疗" 或"公司"）控股子公司上海鸿脉医疗科技有限公司获得国家药品监督管理局颁 发的关于可解脱带纤维毛栓塞弹簧圈的医疗器械注册证，现将相关情况公告如 下： | 产品名称 | 证书编号 | 注册证有效期 | | | | 注册 分类 | 适用范围 | | --- | --- | --- | --- | --- | --- | --- | --- | | 可解脱带纤 | | 2026 | 年 3 | 月 | 11 日 | | 该产品适用于外周血 | | 维毛栓塞弹 | 国械注准 | 年 3 | 至 2031 | | 月 10 | 类 III | 管的动脉瘤、动静脉 | | 簧圈 | 20263130508 | | | | | | 畸形、动静脉瘘的填 | | | | | 日 | | | | 塞。 | 一、医疗器械注册证具体情况 二、对公司的影响 HawkMaster™/龙鸢™可解脱带纤维毛栓塞弹簧圈是公司继 HawkNest™/鹰巢™ 带纤维毛栓塞弹簧圈之后获批上市的第二款弹簧圈栓塞类产品。该产品的上市进 一步丰富了公司在外周动脉领域的产品组合，也进一步完 ...

证券代码：688016 证券简称：心脉医疗 公告编号：2026-005 上海微创心脉医疗科技（集团）股份有限公司 关于胸主多分支支架获美国 FDA 突破性医疗器械认 定的自愿性披露公告 （四） FDA突破性医疗器械认定基本情况 美国FDA突破性医疗器械认定计划（Breakthrough Devices Program）旨在为 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海微创心脉医疗科技（集团）股份有限公司（以下简称"心脉医疗"）创 新研发的Hector®/通天戟™胸主动脉多分支覆膜支架系统（以下简称"Hector胸主 多分支支架"）于2026年2月27日获得美国食品药品监督管理局（FDA）突破性 医疗器械认定（Breakthrough Device Designation）。该产品用于微创伤介入治疗 累及主动脉弓部三分支的胸主动脉病变。现将相关情况公告如下： 一、本次认定的具体情况 （一） 产品名称：Hector®/通天戟™胸主动脉多分支覆膜支架系统 （二） 认定日期：2026年2月27日 （三） 产品基本情况 ...

Financial Performance Summary - The company achieved total operating revenue of 1.3506 billion yuan, an increase of 11.96% year-on-year [2] - Operating profit was 653.89 million yuan, a decrease of 1.10% year-on-year [2] - Total profit reached 653.37 million yuan, a slight increase of 0.18% year-on-year [2] - Net profit attributable to shareholders of the parent company was 563.21 million yuan, up 12.17% year-on-year [2] - The basic earnings per share increased by 14.25% to 4.65 yuan [2] - Total assets at the end of the reporting period were 4.6405 billion yuan, an increase of 8.13% from the beginning of the year [2] - Shareholders' equity attributable to the parent company was 4.0757 billion yuan, up 7.48% from the beginning of the year [2] - Net asset value per share attributable to the parent company was 33.63 yuan, an increase of 9.03% [2] Business Operations and Factors Influencing Performance - The company focused on innovative products, enhancing its domestic leading position while expanding into lower-tier markets and offering customized treatment solutions [3] - Overseas sales revenue exceeded 250 million yuan, growing over 55% year-on-year, contributing to more than 18% of total revenue [3] - The company launched multiple innovative products domestically, including the Cratos branched aortic stent system and other medical devices [3] - The product sales network now covers 49 countries and regions, including China [3] Product Development and Pipeline - The company has a robust pipeline with several products in various stages of development, including the Aegis II abdominal aortic stent system and the Hector thoracic multi-branch stent system [4] - The company is actively pursuing international registrations for its innovative products, including CE and FDA approvals [4] - New peripheral intervention products are expected to be approved for market launch in 2026 [4]

Core Viewpoint - Shanghai MicroPort CardioFlow Medtech Co., Ltd. reported a strong financial performance for the year 2025, with significant growth in revenue and net profit, indicating a positive outlook for the company and its market position [1]. Financial Performance - The company achieved total revenue of 1.351 billion yuan, representing a year-on-year increase of 11.96% [1]. - The net profit attributable to shareholders was 563 million yuan, up 12.17% year-on-year [1]. - The net profit after deducting non-recurring gains and losses was 502 million yuan, reflecting a substantial growth of 26.97% [1]. - Basic earnings per share reached 4.65 yuan, an increase of 14.25% compared to the previous year [1]. Asset and Equity Growth - Total assets amounted to 4.640 billion yuan, showing an 8.13% increase from the beginning of the year [1]. - The equity attributable to shareholders of the parent company was 4.076 billion yuan, which is a 7.48% growth since the start of the year [1]. Market Expansion - The company has accelerated its overseas market expansion, with overseas revenue exceeding 250 million yuan, marking a growth of over 55% [1]. - Products are now sold in 49 countries and regions, indicating a broadening international presence [1].

Major Announcements - Cambrian reported a net profit of 2.059 billion yuan for 2025, turning around from a loss of 450 million yuan in the previous year, with total revenue reaching 6.497 billion yuan, a year-on-year increase of 453.21% [12] - Moer Thread achieved total revenue of 1.506 billion yuan in 2025, marking a year-on-year growth of 243.37%, although it still reported a net loss of 1.024 billion yuan [13] - Zhongji Xuchuang's net profit for 2025 grew by 108.81% year-on-year, reaching 10.799 billion yuan, with total revenue of 38.24 billion yuan, up 60.25% [14] Company Performance Reports - Xirong Environment proposed a cash dividend of approximately 2.35 yuan per 10 shares for 2025, based on a payout ratio of 35% of the net profit attributable to shareholders [2] - Jietu's optical connection business is still in its early stages, contributing less than 5% to total revenue, with growth dependent on various market factors [3] - Zhongying Technology plans to acquire at least 51% of Yingzhong Electric, which specializes in insulation fiber materials [4] - Xibu Superconductor's subsidiary, Juneng Magnet, will be listed on the National Equities Exchange and Quotations starting March 2, 2026 [5] - Ingrity Media announced that some of its bank accounts have had their funds unfrozen, allowing normal operations to resume [6][7] - Dayun Technology plans to establish a joint venture to enhance its semiconductor testing capabilities, with a registered capital of 11 million yuan [7] Financial Highlights - Huazhong Technology reported a net profit of 1.36 billion yuan for 2025, a decrease of 31.19%, despite total revenue increasing by 55.85% to 18.616 billion yuan [36] - Jiangfeng Electronics achieved a net profit of 481 million yuan, up 20.15%, with total revenue of 4.605 billion yuan, a 27.75% increase [20] - Ninebot Company reported a net profit of 1.755 billion yuan, a year-on-year increase of 61.84%, with total revenue of 21.325 billion yuan, up 50.22% [24] - Weicai Technology's net profit reached 300 million yuan, a 134% increase, with total revenue of 1.575 billion yuan, up 46.22% [25] - Dalian Heavy Industry reported a net profit of 588 million yuan, an 18.17% increase, with total revenue of 15.501 billion yuan, up 8.54% [26]

Group 1 - The core viewpoint of the article highlights the significant financial performance of Xinmai Medical, with a reported revenue of approximately 1.351 billion yuan, representing a year-on-year increase of 11.96% [1] - The net profit attributable to shareholders of the listed company is approximately 563 million yuan, reflecting a year-on-year increase of 12.17% [1] - Basic earnings per share are reported at 4.65 yuan, which is a year-on-year increase of 14.25% [1] Group 2 - The article also discusses a notable shift in AI usage, indicating that China's AI invocation volume has surpassed that of the United States for the first time, leading to a surge in various sectors within the A-share market [1] - A well-known Wall Street analyst comments on China's computing power path, suggesting it disrupts traditional perceptions [1]

Core Viewpoint - MicroPort Medical (00853) reported a revenue of approximately 1.351 billion yuan for HeartPulse Medical (688016.SH) in 2025, marking a year-on-year increase of 11.96%, with a net profit attributable to the parent company of about 563 million yuan, up 12.17% year-on-year, and basic earnings per share of 4.65 yuan [1] Group 1: Financial Performance - The total revenue for the reporting period was approximately 1.351 billion yuan, reflecting a year-on-year growth of 11.96% [1] - The net profit attributable to the parent company was around 563 million yuan, showing a year-on-year increase of 12.17% [1] - Basic earnings per share were reported at 4.65 yuan [1] Group 2: Product Development and Market Strategy - The company has accelerated the promotion of new products and replacement of old products through strategies such as market penetration, customized treatment solutions, and product upgrades, leading to a steady increase in market share [1] - The company launched multiple innovative products in the domestic market, including the Cratos branched aortic stent graft system and other medical devices, with a total of 23 products receiving NMPA registration and 11 products obtaining registration in 28 overseas markets [2] - The company has a rich pipeline of products under development, with several products like the Aegis II abdominal aortic stent graft system and Hector thoracic multi-branch stent graft system progressing through various stages of clinical trials and regulatory submissions [3] Group 3: International Sales and Market Expansion - Overseas sales revenue exceeded 250 million yuan, representing a growth of over 55%, contributing to more than 18% of the company's total revenue [1] - The company is actively pursuing collaborations with leading regional clients globally and advancing the market access and promotion of aortic and peripheral interventional products in Europe, Latin America, and Asia-Pacific [1] - The company’s products are now sold in 49 countries and regions, including China [1]

Core Viewpoint - MicroPort Medical (00853) reported HeartCare Medical (688016.SH) 2025 annual performance forecast, showing total revenue of approximately 1.351 billion yuan, a year-on-year increase of 11.96%, and a net profit attributable to the parent company of approximately 563 million yuan, a year-on-year increase of 12.17% [1] Group 1: Financial Performance - Total revenue for the year is approximately 1.351 billion yuan, reflecting a year-on-year growth of 11.96% [1] - Net profit attributable to the parent company is approximately 563 million yuan, with a year-on-year increase of 12.17% [1] - Basic earnings per share stand at 4.65 yuan [1] Group 2: Market Strategy and Sales - The company has strengthened its domestic leading position through strategies such as market penetration, customized treatment solutions, and product upgrades, leading to a steady increase in market share [1] - Overseas sales revenue exceeded 250 million yuan, representing a growth of over 55%, contributing to more than 18% of total revenue [1] - The company is actively promoting its products in Europe, Latin America, and Asia-Pacific, with sales coverage extending to 49 countries and regions [1] Group 3: Product Development and Approvals - Multiple innovative products have been approved for launch in China, including the Cratos branched aortic stent graft system and other medical kits [2] - A total of 23 products have received NMPA registration, and 11 products have been registered in 28 overseas markets [2] - The company has a rich pipeline of products under development, with several products entering various stages of clinical trials and regulatory submissions [3]

证券日报网讯 2月27日，心脉医疗发布公告称，公司2025年实现营业总收入1，350，632，689.26元，同 比增长11.96%；归属于母公司所有者的净利润563，213，122.10元，同比增长12.17%。 （文章来源：证券日报） ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容 而引致之任何損失承擔任何責任。 微創醫療科學有限公司* （於開曼群島註冊成立的有限公司） （股份代號：00853） 1 股東及投資者請注意，以上財務資料根據中國會計準則編製，並僅與心脈醫療科技的業務有關，而 與本集團其他附屬公司無關。該等資料未經審核，且(a)並未撇除集團內交易，(b)並不包括本集團所 有業務，及(c)並不代表或全面反映本集團業務或狀況。 本公司股東及潛在投資者於買賣本公司證券時務請審慎行事。 承董事會命 微創醫療科學有限公司* 上海微創心脈醫療科技（集團）股份有限公司 截至二零二五年十二月三十一日止十二個月未經審核財務資料 以下所載為上海微創心脈醫療科技（集團）股份有限公司（「心脈醫療科技」）截至二零二五年十二月 三十一日止十二個月的未經審核財務資料。本公司持有心脈醫療科技40.32%的股權，其業績於本公 司財務報表合併入賬。心脈醫療科技的股份在上海證券交易所科創板上市。 | | 截至 | 截至 | | | --- | ...